| In Spain, Angelini’s activities in the prescription medicines market are distinguished in the specialty fields of ophthalmology, gynaecology, neuropsychiatry and anti-inflammatory therapies. The package inserts are only intended to provide information for a correct use of drugs and to promote a responsible and sound culture of health. | ||||||||||||||||||||||||||||||||||||||||
| Ophthalmology The pharmaceuticals marketed are mainly anti-infective drugs indicated for the treatment of corneal ulcers and superficial ocular infections; anti-inflammatory drugs used for the treatment of chronic non-infectious conjunctivitis and postoperative ocular inflammation and pain; anti-allergic drugs indicated for allergic seasonal conjunctivitis; ocular lubricants and artificial tears that protect against dry eyes. For the treatment of eye disorders induced by vascular diseases, Angelini is also engaged in the manufacture of an antiplatelet drug containing ditazole as well as of a medicinal product containing a combination of vincamine and piracetam indicated for the treatment of vascular processes occurring in the brain.
| ||||||||||||||||||||||||||||||||||||||||
 top | ||||||||||||||||||||||||||||||||||||||||
Gynaecology The Angelini gynaecological drugs offer solutions to the various intimate and delicate problems a woman may encounter throughout her life: from the treatment of menopausal symptoms and osteoporosis to the treatment of infertility and of threatened miscarriage, from the prevention of congenital and neurological diseases of the foetus during pregnancy to anti-inflammatory and antiseptic drugs for vaginal use. In particular, benzydamine is a nonsteroidal anti-inflammatory drug which was developed by the Angelini research laboratories and is now marketed in Italy, Spain and Portugal.
| ||||||||||||||||||||||||||||||||||||||||
| top | ||||||||||||||||||||||||||||||||||||||||
Neuropsychiatry In the field of neuropsychiatry, Angelini develops and markets pharmaceuticals for the treatment of depression, insomnia and cognitive impairment. Mental and mood disorders are becoming more frequent in all Western societies and are increasingly recognized. According to the WHO estimates, depression and anxiety disorders will be the second cause of social disability in 2020 and will account for more than 5% of all diseases worldwide. Angelini has been operating in this specialty field since the early Seventies with the marketing of trazodone, an antidepressant developed by the Angelini research laboratories and registered in many countries, including the United States.
| ||||||||||||||||||||||||||||||||||||||||
| top | ||||||||||||||||||||||||||||||||||||||||
Anti-Inflammatory Pharmaceuticals Angelini’s activities in the Spanish anti-inflammatory pharmaceuticals market cover drugs containing diclofenac, aceclofenac, chondroitin and ibuprofen. Ibuprofen is also indicated for paediatric patients, to relieve mild to moderate pain in children and to reduce fever. The other anti-inflammatory pharmaceuticals are indicated, in particular, for the treatment of arthrosis, rheumatism and pain affecting the bone, joint and muscle system.
| ||||||||||||||||||||||||||||||||||||||||
| top | ||||||||||||||||||||||||||||||||||||||||
Other Pharmaceuticals To complete its portfolio of prescription medicines, Angelini also markets a drug for the treatment of chronic venous insufficiency, a vasodilatory for the treatment of cognitive impairment and an anti-migraine drug.
| ||||||||||||||||||||||||||||||||||||||||
| top |
Go to angelini site